IMPT-514's dual CAR approach is designed to
ablate B-cells and pathogenic CD20+ T cells for potential
therapeutic benefit in MS
LOS
ANGELES, May 21, 2024 /PRNewswire/ -- ImmPACT
Bio USA Inc. (ImmPACT Bio), a
clinical-stage biopharmaceutical company developing a new
generation of cellular therapies that have the potential to bring
transformational benefits to patients, today announced that it will
present new preclinical data supporting the potential therapeutic
benefit of IMPT-514 for the treatment of multiple sclerosis (MS).
IMPT-514 is ImmPACT Bio's CD19/CD20 bispecific chimeric antigen
receptor (CAR) T-cell therapy product candidate. These new data
will be delivered in a poster presentation at the Consortium of
Multiple Sclerosis Centers (CMSC) Annual Meeting, taking place in
Nashville, Tennessee from
May 28 – June
1, 2024.
"Multiple sclerosis is a chronic autoimmune disorder which
affects the central nervous system (CNS) that is driven by
autoreactive immune cells. B-cell depletion using an anti-CD20
approach has demonstrated clinical benefit, but poor tissue
penetration has limited activity in the CNS," said Sumant
Ramachandra, M.D., Ph.D., chief executive officer of ImmPACT Bio.
"Recently, a subset of CD20-expressing T-cells was identified as a
contributor to the pathogenesis of MS. Here, we are exploring the
potential of our CAR T-cell therapy product candidate, IMPT-514,
and its unique dual-targeting CAR design to ablate multiple
potentially pathogenic autoimmune subsets including antibody
secreting B-cells and CD20+ T-cells for potential therapeutic
benefit in MS. To our knowledge, IMPT-514 is the
first-and-only CD19/CD20 CAR T-cell therapy in autoimmune
diseases."
Details for the presentation are as follows:
Title: Manufacturing of CD19/CD20 Bispecific CAR
T-Cell Therapy (IMPT-514) for the Treatment of Multiple
Sclerosis
Abstract Number: LB04
Presenter: Ethan BenDavid, ImmPACT Bio
Poster Session Date/Time: Thursday,
May 30, 2024 at 5:15 – 7:15 PM
ET
Location: Music City Center, Exhibit Hall AB
Abstracts and additional details can be found at the CMSC Annual
Meeting website.
About IMPT-514
IMPT-514 is a CD19/CD20-targeting CAR
T-cell therapy that utilizes a potent bispecific CAR and a 4-1BB
costimulatory domain. It is the same CAR construct as ImmPACT's
IMPT-314, which is under development for aggressive B-cell
non-Hodgkin's lymphoma. In preclinical studies, we have shown that
we can routinely manufacture, at research scale, IMPT-514 from
patients across multiple autoimmune diseases who were heavily
treated with immunosuppressive agents and demonstrated elimination
of autologous B-cells and a moderate cytokine profile.
About ImmPACT Bio
ImmPACT Bio USA, Inc., is a clinical-stage
biopharmaceutical company developing a new generation of cellular
therapies that have the potential to bring transformational
benefits to patients. The company's logic-gate-based CAR T-cell
platforms, licensed from University of
California, Los Angeles (UCLA)
Technology Development Group, are specifically designed to deplete
B cells, prevent antigen escape, and overcome the immunosuppressive
tumor microenvironment. The company's technology is based on the
work of pioneering scientists, Yvonne
Chen, Ph.D., and Antoni
Ribas, M.D., Ph.D., both from UCLA. For more information, visit
http://www.immpact-bio.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/immpact-bio-to-present-new-preclinical-data-for-cd19cd20-bispecific-car-t-cell-therapy-in-multiple-sclerosis-302150609.html
SOURCE ImmPACT Bio USA Inc.